Treatment of anaerobic infection

被引:47
作者
Brook, Itzhak [1 ,2 ]
机构
[1] Georgetown Univ, Sch Med, Dept Pediat, Washington, DC 20016 USA
[2] Georgetown Univ, Sch Med, Dept Med, Washington, DC 20016 USA
关键词
anaerobes; antibiotics; Bacteroides; Fusobacterium; Peptostreptococci; Prevotella;
D O I
10.1586/14787210.5.6.991
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Anaerobic bacteria are the predominant flora in the normal human skin and mucous membranes and are, therefore, a common cause of endogenous infections. Since anaerobic infections are generally polymicrobial, where anaerobes are mixed with aerobic organisms, therapy should provide coverage of both types of pathogens. The isolation of anaerobes requires appropriate methods of collection, transportation and cultivation of specimens. The lack of use of any of these methods can lead to inadequate recovery of anaerobes and inappropriate therapy. Treatment of anaerobic infection is complicated by the slow growth of these organisms and the growing resistance of anaerobic bacteria to antimicrobials. The primary role of antimicrobials is to limit the local and systemic spread of infection. Surgical drainage is of primary importance. This includes debriding of necrotic tissue, draining the pus, improving circulation, alleviating obstruction and increasing tissue oxygenation. The most effective antimicrobials against anaerobic organisms are metronidazole, the carbapenems (imipenem, meropenern and ertapenem), chloramphenicol, the combinations of a penicillin and a beta-lactamase inhibitor (ampicillin or ticarcillin plus clavulanate, amoxicillin plus sulbactam, and piperacillin plus tozobactam), tigecycline and clindamycin.
引用
收藏
页码:991 / 1006
页数:16
相关论文
共 109 条
[61]   Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada [J].
Labbé, AC ;
Bourgault, AM ;
Vincelette, J ;
Turgeon, PL ;
Lamothe, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2517-2519
[62]   Reemergence of anaerobic bacteremia [J].
Lassmann, Britta ;
Gustafson, Daniel R. ;
Wood, Christina M. ;
Rosenblatt, Jon E. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (07) :895-900
[63]  
Laterre PF, 2006, ACTA CHIR BELG, V106, P2
[64]   Emerging resistance of anaerobic bacteria to antimicrobial agents in south Korea [J].
Lee, K ;
Chong, Y ;
Jeong, SH ;
Xu, XS ;
Kwon, OH .
CLINICAL INFECTIOUS DISEASES, 1996, 23 :S73-S77
[65]   CLINDAMYCIN [J].
LEFROCK, JL ;
MOLAVI, A ;
PRINCE, RA .
MEDICAL CLINICS OF NORTH AMERICA, 1982, 66 (01) :103-120
[66]   Intra-abdominal infections [J].
Marshall, JC .
MICROBES AND INFECTION, 2004, 6 (11) :1015-1025
[67]   Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics [J].
Munckhof, WJ ;
Carney, J ;
Neilson, G ;
Neilson, J ;
Carroll, J ;
McWhinney, B ;
Whitby, M .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (06) :514-522
[68]   Clostridium difficile-associated diarrhea -: A review [J].
Mylonakis, E ;
Ryan, ET ;
Calderwood, SB .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (04) :525-533
[69]   Successful treatment of brainstem abscess with stereotactic aspiration [J].
Nakajima, H ;
Iwai, Y ;
Yamanaka, K ;
Kishi, H .
SURGICAL NEUROLOGY, 1999, 52 (05) :445-448
[70]   Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections [J].
Nau, R ;
Sörgel, F ;
Prange, HW .
CLINICAL PHARMACOKINETICS, 1998, 35 (03) :223-246